Accesswire
06 Jul 2026, 07:05 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
BioNxt has moved its sublingual Semaglutide oral dissolvable film (ODF) program into the next stage of pharmaceutical development, including formulation optimization and compatibility testing. — Progressing a delivery platform for a high-demand GLP-1 drug reduces technical risk and moves the company closer to potential clinical trials or partnership.
+0.50The company is designing the ODF to bypass the gastrointestinal tract and hepatic first-pass metabolism, targeting a needle-free alternative to current GLP-1 injectables. — A successful non-invasive delivery method for peptides would significantly increase patient adherence and market reach, though it remains in early development.
+0.30BioNxt intends to use the Semaglutide program to establish a scalable sublingual ODF platform for other complex peptide-based therapeutics and CNS disorders. — Expanding the utility of the platform beyond one drug increases the company's total addressable market and diversification potential.
+0.20Continue reading
6 related stories
Search tags
Which stocks this story touches
The company is advancing its GLP-1 sublingual Semaglutide ODF program into the next stage of development.
Morgan Stanley is mentioned only as a source of market research estimates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
1d ago
